Immunome Inc. announced positive topline results from the global pivotal Phase 3 RINGSIDE trial evaluating varegacestat, an investigational oral gamma secretase inhibitor, in patients with progressing desmoid tumors.
Immunome shares surged 36% on the news.
The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival for varegacestat compared to placebo (hazard ratio = 0.16, p<0.0001). All key secondary endpoints were also met, including an objective response rate of 56%. Varegacestat was generally well tolerated with a manageable safety profile. Immunome plans to submit a New Drug Application to the U.S. FDA in the second quarter of 2026 and intends to present additional data from the RINGSIDE trial at an upcoming major medical conference. Topline results were announced and discussed during a webcast and conference call, with further detailed data presentation planned for the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215845554) on December 15, 2025, and is solely responsible for the information contained therein.
